Developer docs
API playgroundTry for free, no card

Search company profiles

elitek

Full company profile

uuid02m7qxw

Namestring
elitek
Legal namestring
Sanofi
Websiteurl
elitekpro.com
Company typeenum
Public
Founded yearstring
-
Descriptiontext

ELITEK (rasburicase) is a Sanofi-marketed biopharmaceutical product indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to cause Tumor Lysis Syndrome (TLS) and subsequent hyperuricemia. The active ingredient, rasburicase, is a recombinant DNA-derived urate oxidase enzyme that catalytically degrades uric acid into allantoin, a more soluble and renally excretable metabolite. In a Phase 3 trial, prophylactic ELITEK maintained plasma uric acid at ≤7.5 mg/dL in 87% of patients versus 66% for allopurinol between days 3 and 7 (P=0.001). The product has been FDA-approved for over 20 years, is indicated for only a single course of treatment, and carries a boxed warning for hypersensitivity reactions, hemolysis (including G6PD-deficiency contraindication), methemoglobinemia, and interference with uric acid laboratory measurements.

The technology platform is a single-asset, single-mechanism biologic with no disclosed pipeline extensions. Commercially, ELITEK is marketed to US oncologists, hematologists, and pediatric oncologists through Sanofi's pharmaceutical sales force and the Sanofi Pro Campus HCP portal, which provides clinical data, dosing guidance, mechanism-of-action content, and patient-risk-factor resources. Distribution is handled through specialty pharmacies, pharmaceutical wholesalers, and direct purchase channels for healthcare facilities, with cold-chain handling requirements due to the biologic nature of the product.

ELITEK generates revenue through prescription product sales to hospitals, oncology clinics, and specialty pharmacies that dispense the drug to patients undergoing chemotherapy. Pricing is not publicly disclosed; procurement occurs through Sanofi's account relationships and specialty pharmacy partners. The product is positioned within Sanofi's broader specialty biologics portfolio alongside Thyrogen, ALPROLIX, and other rare disease and oncology assets that are managed through the Genzyme-era commercial infrastructure Sanofi acquired.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersBridgewater, United States
HQ citystring
Bridgewater
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
tumor lysis syndrome treatment, recombinant urate oxidase, hyperuricemia management, oncology biologic drug, uric acid reduction
Industry4 codes
PRIMARYHLAKAHAM
Onconephrology (Kidney Care in Cancer Patients)
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
Product category
Oncology Biopharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales
TypeOne Time License
Description

ELITEK is a prescription biopharmaceutical product sold to healthcare facilities and through specialty pharmacy channels. Revenue is generated through product sales to hospitals, clinics, and specialty pharmacies that dispense the drug to patients undergoing anticancer therapy.

pro.campus.sanofi
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Sanofi Campus
Description

Healthcare professional portal providing product information and resources

pro.campus.sanofi
+2 more records
Core offering1 text field

ELITEK (rasburicase) is a prescription recombinant urate oxidase enzyme biologic administered as an IV infusion for the initial management of plasma uric acid levels in pediatric and adult patients with hematologic malignancies and solid tumors who are receiving anticancer therapy expected to cause tumor lysis. It is sold by Sanofi through specialty pharmacies, wholesalers, and direct institutional purchasing to hospitals, clinics, and oncology treatment centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 87% of patients maintained normal uric acid levels (≤7.5 mg/dL) vs 66% for allopurinol (P=0.001) between 3-7 days after treatment initiation
Product overview1 text field

ELITEK (rasburicase) is a pharmaceutical product for the management of tumor lysis syndrome. The company operates a multi-product pharmaceutical portfolio including therapeutic biologics, vaccines, and small molecule medications across therapeutic areas including oncology (ELITEK), hematology (ALPROLIX for hemophilia B), cardiovascular (AVAPRO/AVALIDE for hypertension), vaccines (MenQuadfi for meningococcal disease, NUVAXOVID for COVID-19), endocrinology (Thyrogen for thyroid cancer), and pediatrics/infectious disease (Beyfortus for RSV prevention in infants). These products are distributed through the Sanofi Campus HCP portal.

Product and service1 record
1ELITEK (rasburicase) for injection
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Horizon Therapeutics (Amgen)
TypeDirect peer
Description

Markets Krystexxa (pegloticase), a recombinant uricase enzyme for chronic refractory gout, the closest mechanism analog to ELITEK's rasburicase. Both are parenteral biologics that enzymatically degrade uric acid and are positioned in specialty/rare disease channels, making Horizon the most directly comparable peer for ELITEK's recombinant urate oxidase platform.

TypeBroad incumbent
Description

Markets Uloric (febuxostat), an oral xanthine oxidase inhibitor for chronic hyperuricemia/gout, and has a broader oncology supportive care and rare disease portfolio. Comparable as a competitor in the broader uric acid-lowering therapeutic space and as a specialty/oncology pharma incumbent.

TypeBroad incumbent
Description

Major oncology supportive care franchise including Neulasta (pegfilgrastim) and Nplate (romiplostim); also the parent of Horizon Therapeutics/Krystexxa. Comparable as a large incumbent operating biologic supportive care products in similar hospital/specialty pharmacy channels.

TypeEmerging player
Description

Specialty biopharma focused on oncology and rare diseases with hospital-administered products. Comparable as a specialty pharma operating niche hospital-channel therapeutics with similar distribution and HCP-targeted commercial approaches.

TypeEmerging player
Description

Specialty rare disease biopharma with a portfolio spanning hematology, oncology supportive care, and immunology. Comparable as a focused rare-disease/specialty pharma commercializing niche biologics through specialty pharmacy channels.

TypeBroad incumbent
Description

Specialty rare disease unit of AstraZeneca commercializing biologics in ultra-rare and rare conditions. Comparable as a large specialty/rare disease commercial organization operating hospital-administered biologics with similar payer engagement and specialty distribution models.

TypeEmerging player
Description

Specialty pharma focused on rare diseases and oncology supportive care, with hospital-administered products. Comparable as a specialty distributor/marketer of niche hospital therapeutics operating in similar channels.

8Bristol-Myers Squibb
TypeBroad incumbent
Description

Large oncology-focused pharma with a portfolio spanning hematology and solid tumor therapeutics; operates supportive care adjacencies in oncology. Comparable as a broad incumbent in oncology/hematology with similar institutional customer base.

TypeBroad incumbent
Description

Specialty/oncology pharma with hospital-administered biologics and rare disease products. Comparable as a large specialty pharma incumbent operating in oncology and rare disease supportive care.

TypeBroad incumbent
Description

Large pharma with a substantial oncology supportive care portfolio and biosimilars business. Comparable as a broad incumbent that both competes in oncology supportive care biologics and represents a potential future biosimilar entrant into the recombinant urate oxidase space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

elitek

Oncology Biopharmaceuticalselitekpro.com

What elitek does

ELITEK (rasburicase) is a Sanofi-marketed biopharmaceutical product indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to cause Tumor Lysis Syndrome (TLS) and subsequent hyperuricemia. The active ingredient, rasburicase, is a recombinant DNA-derived urate oxidase enzyme that catalytically degrades uric acid into allantoin, a more soluble and renally excretable metabolite. In a Phase 3 trial, prophylactic ELITEK maintained plasma uric acid at ≤7.5 mg/dL in 87% of patients versus 66% for allopurinol between days 3 and 7 (P=0.001). The product has been FDA-approved for over 20 years, is indicated for only a single course of treatment, and carries a boxed warning for hypersensitivity reactions, hemolysis (including G6PD-deficiency contraindication), methemoglobinemia, and interference with uric acid laboratory measurements.

The technology platform is a single-asset, single-mechanism biologic with no disclosed pipeline extensions. Commercially, ELITEK is marketed to US oncologists, hematologists, and pediatric oncologists through Sanofi's pharmaceutical sales force and the Sanofi Pro Campus HCP portal, which provides clinical data, dosing guidance, mechanism-of-action content, and patient-risk-factor resources. Distribution is handled through specialty pharmacies, pharmaceutical wholesalers, and direct purchase channels for healthcare facilities, with cold-chain handling requirements due to the biologic nature of the product.

ELITEK generates revenue through prescription product sales to hospitals, oncology clinics, and specialty pharmacies that dispense the drug to patients undergoing chemotherapy. Pricing is not publicly disclosed; procurement occurs through Sanofi's account relationships and specialty pharmacy partners. The product is positioned within Sanofi's broader specialty biologics portfolio alongside Thyrogen, ALPROLIX, and other rare disease and oncology assets that are managed through the Genzyme-era commercial infrastructure Sanofi acquired.

elitek firmographics

Firmographics
Name
elitek
Legal name
Sanofi
Website
https://elitekpro.com
Company type
Public
Operating status
Operating
Ownership category
akta.pro rank

elitek industry classification

Industry
Product category
Oncology Biopharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
akta.pro industry
PRIMARYHLAKAHAM
Onconephrology (Kidney Care in Cancer Patients)
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIAIAI
Rare Renal & Nephrology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Tumor lysis syndrome treatment
  • Recombinant urate oxidase
  • Hyperuricemia management
  • Oncology biologic drug
  • Uric acid reduction

Where elitek is headquartered

Location

Headquarters

HQ city
Bridgewater
HQ country
United States
HQ region
North America

Offices1 record

Markets served

elitek business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Pharmaceutical product sales: ELITEK is a prescription biopharmaceutical product sold to healthcare facilities and through specialty pharmacy channels. Revenue is generated through product sales to hospitals, clinics, and specialty pharmacies that dispense the drug to patients undergoing anticancer therapy.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels1 record

elitek product offering

Product offering

Core offering

ELITEK (rasburicase) is a prescription recombinant urate oxidase enzyme biologic administered as an IV infusion for the initial management of plasma uric acid levels in pediatric and adult patients with hematologic malignancies and solid tumors who are receiving anticancer therapy expected to cause tumor lysis. It is sold by Sanofi through specialty pharmacies, wholesalers, and direct institutional purchasing to hospitals, clinics, and oncology treatment centers.

Product overview

ELITEK (rasburicase) is a pharmaceutical product for the management of tumor lysis syndrome. The company operates a multi-product pharmaceutical portfolio including therapeutic biologics, vaccines, and small molecule medications across therapeutic areas including oncology (ELITEK), hematology (ALPROLIX for hemophilia B), cardiovascular (AVAPRO/AVALIDE for hypertension), vaccines (MenQuadfi for meningococcal disease, NUVAXOVID for COVID-19), endocrinology (Thyrogen for thyroid cancer), and pediatrics/infectious disease (Beyfortus for RSV prevention in infants). These products are distributed through the Sanofi Campus HCP portal.

Differentiator

Problem solved

Functional benefit

Brands

  • Sanofi Campus: Healthcare professional portal providing product information and resources
  • ThyrogenONE
  • HemAssist

Products and services

  • ELITEK (rasburicase) for injection

Quantifiable outcome

  • 87% of patients maintained normal uric acid levels (≤7.5 mg/dL) vs 66% for allopurinol (P=0.001) between 3-7 days after treatment initiation

Companies that use elitek

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

elitek technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

elitek partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights2 records

elitek competitors and assessment

Company assessment

Direct peers

  • Horizon Therapeutics (Amgen): Markets Krystexxa (pegloticase), a recombinant uricase enzyme for chronic refractory gout, the closest mechanism analog to ELITEK's rasburicase. Both are parenteral biologics that enzymatically degrade uric acid and are positioned in specialty/rare disease channels, making Horizon the most directly comparable peer for ELITEK's recombinant urate oxidase platform.

Broad incumbents

  • Takeda Pharmaceutical: Markets Uloric (febuxostat), an oral xanthine oxidase inhibitor for chronic hyperuricemia/gout, and has a broader oncology supportive care and rare disease portfolio. Comparable as a competitor in the broader uric acid-lowering therapeutic space and as a specialty/oncology pharma incumbent.
  • Amgen: Major oncology supportive care franchise including Neulasta (pegfilgrastim) and Nplate (romiplostim); also the parent of Horizon Therapeutics/Krystexxa. Comparable as a large incumbent operating biologic supportive care products in similar hospital/specialty pharmacy channels.
  • Alexion (AstraZeneca Rare Disease): Specialty rare disease unit of AstraZeneca commercializing biologics in ultra-rare and rare conditions. Comparable as a large specialty/rare disease commercial organization operating hospital-administered biologics with similar payer engagement and specialty distribution models.
  • Bristol-Myers Squibb: Large oncology-focused pharma with a portfolio spanning hematology and solid tumor therapeutics; operates supportive care adjacencies in oncology. Comparable as a broad incumbent in oncology/hematology with similar institutional customer base.
  • Astellas Pharma: Specialty/oncology pharma with hospital-administered biologics and rare disease products. Comparable as a large specialty pharma incumbent operating in oncology and rare disease supportive care.
  • Pfizer: Large pharma with a substantial oncology supportive care portfolio and biosimilars business. Comparable as a broad incumbent that both competes in oncology supportive care biologics and represents a potential future biosimilar entrant into the recombinant urate oxidase space.

Emerging players

  • Jazz Pharmaceuticals: Specialty biopharma focused on oncology and rare diseases with hospital-administered products. Comparable as a specialty pharma operating niche hospital-channel therapeutics with similar distribution and HCP-targeted commercial approaches.
  • Swedish Orphan Biovitrum (Sobi): Specialty rare disease biopharma with a portfolio spanning hematology, oncology supportive care, and immunology. Comparable as a focused rare-disease/specialty pharma commercializing niche biologics through specialty pharmacy channels.
  • Recordati Rare Diseases: Specialty pharma focused on rare diseases and oncology supportive care, with hospital-administered products. Comparable as a specialty distributor/marketer of niche hospital therapeutics operating in similar channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

elitek financial estimates

Financial estimate

Revenue estimate

Valuation estimate

elitek leadership team

Management profile

Number of profiles

elitek subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

elitek funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

elitek M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about elitek

What does elitek do?

ELITEK (rasburicase) is a prescription recombinant urate oxidase enzyme biologic administered as an IV infusion for the initial management of plasma uric acid levels in pediatric and adult patients with hematologic malignancies and solid tumors who are receiving anticancer therapy expected to cause tumor lysis. It is sold by Sanofi through specialty pharmacies, wholesalers, and direct institutional purchasing to hospitals, clinics, and oncology treatment centers.

Is elitek a public or private company?

elitek is a public company. It is classified as corporate owned and is currently operating.

When was elitek founded?

elitek was founded in -1.

Where is elitek based?

elitek is headquartered in Bridgewater, United States, in the North America region.

How does elitek make money?

One revenue line is on record: pharmaceutical product sales.

Who are elitek's main competitors?

Horizon Therapeutics (Amgen) is listed as a direct peer. Broad incumbents are Takeda Pharmaceutical, Amgen, Alexion (AstraZeneca Rare Disease), Bristol-Myers Squibb, Astellas Pharma and Pfizer. Emerging players are Jazz Pharmaceuticals, Swedish Orphan Biovitrum (Sobi) and Recordati Rare Diseases.

Does elitek have an API?

No public API is recorded for elitek.

What industry is elitek in?

elitek's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAKAHAM, Onconephrology (Kidney Care in Cancer Patients), with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 3254.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales